Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation

Table 5 Number of studies reporting parameters which could influence the cost-effectiveness results

Therapeutic area	Epidemiological and disease progression parameters				Clinical effectiveness data		Resource use and cost parameters
Therapeutic area	probability of ADRs	allele frequency	PPV/NPV	mortality rate of ADRs	efficacy of genetic testing	efficacy of drugs treatment	cost of testing	costs of alternative drugs	cost of hospitalization
Cardiovascular disease (n = 24)
CYP2C19 -Clopidogrel	[30, 33, 34]			[31]		[35]		[36]	[38]
CYP2C9 and VKORC1 -Warfarin	[17, 21, 25]				[16, 22, 26, 28, 29]		[23, 24]	[19]
pharmacogenetic testing-Statin						[39]
Gout (n = 8)
HLA-B58:01* -Allopurinol	[43, 44, 46]	[45]				[40]	[42]	[44]	[40, 47]
HIV infection (n = 8)
HLA-B57:01* -Abacavir		[50]		[49]			[51, 52]	[53, 54]
CYP2B6 -Efavirenz							[55]
Autoimmune disease (n = 8)
TPMT - Azathioprine		[57]	[62]		[63]		[56, 58]	[60]
Epilepsy/neuropathic pain (n = 6)
HLA-B15:02* or HLA-A31:01* -Carbamazepine			[67, 68]			[64, 69]		[65, 67]
Cancer (n = 3)
UGT1A1 -Irinotecan					[71]	[72]
DPYD -Fluoropyrimidine	[70]
Major depressive disorder (n = 1)
CYP2D6 -Nortriptyline					[73]	[73]
Hormone replacement therapy (n = 1)
Factor V Leiden-Estrogen combined in oral contraceptives

ADRs: Adverse Drug Reactions, PPV: Positive Predictive Value, NPV: Negative Predictive Value

ISSN: 1472-6963